April 22, 2026: Removed from Category 2 On April 15, 2026, the FDA published a 503A category revision removing 12 peptides from Category 2 effective seven calendar days later (April 22)
This prevents other nutrients from competing for absorption, although liposomal formats are much more resilient to the presence of food than standard capsules
In this hearing, experts will be called to testify about several matters, including how to reliably diagnose gastroparesis (paralysis of the gut)
Personnel handling it within an authorised investigational context must refer to the sponsor's IMPD or equivalent documentation, which will contain validated stability data and storage requirements specific to the formulation under study
Collagen, Elastin, and Glycosaminoglycan Pathways Pre-clinical data points to increased synthesis of collagen, elastin, and glycosaminoglycans following GHK-Cu exposure in fibroblast cultures [2][3]